Curis, Inc.
Clinical trials sponsored by Curis, Inc., explained in plain language.
-
New drug duo aims to wipe out hidden leukemia cells
Disease control Recruiting nowThis study tests whether adding emavusertib to a standard targeted therapy (zanubrutinib) can better control chronic lymphocytic leukemia and related B-cell cancers. About 108 adults with these cancers will receive the combination. The goal is to see if the combo can make cancer …
Phase: PHASE2 • Sponsor: Curis, Inc. • Aim: Disease control
Last updated May 26, 2026 07:43 UTC
-
New pill combo shows promise for tough brain cancer
Disease control Recruiting nowThis study tests an experimental oral drug called emavusertib, taken alone or with another drug (ibrutinib), in adults with a rare brain lymphoma that has returned or stopped responding to prior therapy. The goal is to find safe doses and see if the combination can shrink tumors …
Phase: PHASE1, PHASE2 • Sponsor: Curis, Inc. • Aim: Disease control
Last updated May 22, 2026 14:05 UTC